Myelodysplastic syndrome
Not recruitingStudy Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions
Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions
- Disease:Myelodysplastic syndrome
- Substances:Epoetin AlfaLuspatercept
Germany- Participants:18–64 years · 65+ years
- Substances:Epoetin Alfa
- Sponsor:Celgene Corp.













